Targeted therapies for high-risk acute myeloid leukemia

Hematology/Oncology Clinics of North America

Volumn 15, Issue 4, 2001, Pages 677-701

  Perentesis, John P ^a   Sievers, Eric L ^b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BMS 21466; CALICHEAMICIN; CD33 ANTIGEN; CD45 ANTIGEN; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IMATINIB; IODINE 131; MONOCLONAL ANTIBODY; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; RADIOISOTOPE; RETINOIC ACID; TIPIFARNIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; CARCINOGENESIS; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME INHIBITION; GENE MUTATION; GENE TARGETING; HIGH RISK POPULATION; HUMAN; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0034793548     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70242-2     Document Type: Article

References (147)

1. Mutant ras epitopes as targets for cancer vaccines
2. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
3. Characterization of the human ABC superfamily: Isolation and mapping of 21 new genes using the expressed sequence tags database
4. Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia
5. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties
6. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies
7. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia
8. Clinical significance of P-glycoprotein in multidrug resistance malignancies
9. Ras oncogenes: Their role in neoplasia
10. RAS and leukemia: From basic mechanisms to gene-directed therapy
11. Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells
12. A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor
13. Refined structure of dimeric diphtheria toxin at 2.0 A resolution
14. Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed
15. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia
16. Isolation and characterization of an anthracycline-resistant human leukemic cell line
17. Loss of NF 1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells
18. All in the family? New insights and questions regarding interconnectivity of Ras, Rap 1 and Ral
19. Interleukin-1 is one factor which regulates autocrine production of GM-CSF by the blast cells of acute myeloblastic leukaemia
20. Role of autocrine and paracrine production of granulocyte-macrophage colony-stimulating factor and interleukin-1 beta in the autonomous growth of acute myeloblastic leukemia cells - Studies using purified CD34-positive cells
21. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors
22. Interleukin-3 and granulocyte-monocyte colony-stimulating factor receptors on human acute myelocytic leukemia cells and relationship to the proliferative response
23. Surface and cytoplasmic expression of CD 45 antigen isoforms in normal and malignant myeloid cell differentiation
24. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis
25. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies
26. Supersaturating infusional humanized anti-CD 33 monoclonal antibody HuM195 in myelogenous leukemia
27. Anti-CD 33 monoclonal antibody M195 for the therapy of myeloid leukemia
28. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
29. Structure and expression of genes of GMCSF and G-CSF in blast cells from patients with acute myeloblastic leukemia
30. The crystal structure of diphtheria toxin
31. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remissio: A randomized trial of two irradiation regimens
32. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens
33. Chimeric and humanized antibodies with specificity for the CD 33 antigen
34. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
35. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP
36. Structural and signaling requirements for BCRABL-mediated transformation and inhibition of apoptosis
37. Definition of a standard-risk group in children with AML
38. Philadelphia chromosome positive childhood acute lymphoblastic leukemia: Clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study
39. Activation of the CPP32 protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents
40. Novel fold and putative receptor binding site of granulocyte-macrophage colony-stimulating factor
41. Expression of normal myeloid-associated antigens by acute leukemia cells
42. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
43. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
44. Effects of a selective inhibitor of the abl tyrosine kinase on the growth of bcr-abl positive cells
45. The biochemistry of P-glycoprotein-mediated multidrug resistance
46. The biology of chronic myeloid leukemia
47. Humanized monoclonal anti-CD33 antibody HuM195 in the treatment of relapsed/refractory acute myelogenous leukemia (AML): Preliminary report of a phase II study
48. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia
49. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome
50. Apoptosis in cancer therapy: Crossing the threshold
51. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF
52. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for phase I clinical trials
53. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics
54. Mutated Ras peptides as vaccines in immunotherapy of cancer
55. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
56. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia
57. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells
58. Complete exon-intron organization of the human leukocyte common antigen (CD45) gene
59. Clinical implications of the p53 tumor-suppressor gene
60. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics
61. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
62. Famesol modification of Kirsten-ras exon 4B protein is essential for transformation
63. Molecular remission induction with retinoic acid and anti-CD 33 monoclonal antibody HuM195 in acute promyelocytic leukemia
64. Potential for myeloablation with yttrium-90HuM195 (anti-CD33) in myeloid leukemia
65. Phase I trial of targeted alpha-particle therapy for myeloid leukemias with bismuth-213- HuM195 (Anti-CD33)
66. Induction of apoptosis by cancer chemotherapy
67. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors
68. The release of cytochrome c from mitochondria: A primary site for Bcl- 2 regulation of apoptosis
69. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia
70. Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells
71. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: Prognostic implications
72. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP 1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study
73. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin- 2
74. P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells
75. Mttltidrug resistance: Molecular mechanisms and clinical relevance
76. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
77. Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli
78. Acute myeloid leukemia
79. Multidrug resistance (mdrl) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity
80. Isolation and characterization of adriamycin-resistant HL- 60 cells which are not defective in the initial intracellular accumulation of drug
81. Diphtheria antitoxin levels in the 14-30-year age group in Italy
82. Radiolabeled anti-CD 45 monoclonal antibodies target lymphohematopoietic tissue in the macaque
83. Phase I study of (131)I-anti-CD 45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome
84. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
85. Autocrine growth mechanisms of the progenitors of blast cells in acute myeloblastic leukemia
86. P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance
87. Diphtheria booster vaccination: One or two injections?
88. Human homologue of murine T200 glycoprotein
89. IL-3 inhibits the binding of GM-CSF to AML blasts, but the two cytokines act synergistically in supporting blast proliferation
90. Characterization of granulocytemacrophage colony-stimulating factor receptor on the blast cells of acute myeloblastic leukemia
91. Interleukin-3, GM-CSF, and G-CSF receptor expression on cell lines and primary leukemia cells: Receptor heterogeneity and relationship to growth factor responsiveness
92. Granulocyte-macrophage colony-stimulating factor receptor-targeted therapy of chemotherapy- and radiation-resistant human myeloid leukemias
93. In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor
94. Protein toxin inhibitors of protein synthesis
95. Induction of apoptosis in multidrugresistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor
96. MDR1 gene expression and treatment outcome in acute myeloid leukemia
97. Childhood leukemias
98. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia
99. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway
100. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood
101. What is the precise role of human MDR 1 protein in chemotherapeutic drug resistance?
102. Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells
103. Acute myelogenous leukemia in adults
104. Autocrine growth factors and leukaemic haemopoiesis
105. Antitumor activity of DAB389IL- 2 fusion toxin in mycosis fungoides
106. Marrow transplantation for children in first remission of acute nonlymphoblastic leukemia: An update
107. MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia
108. Chronic myelomonocytic leukemia: Tel-a-kinase what ets all about
109. A phase I trial of monoclonal antibody M 195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide
110. Monoclonal antibody M 195: A diagnostic marker for acute myelogenous leukemia
111. A gene expression database for the molecular pharmacology of cancer
112. Structural mechanism for STI- 571 inhibition of abelson tyrosine kinase
113. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia
114. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia
115. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
116. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1
117. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD 33 calichearricin immunoconjugate
118. Efficacy and safety of Gemtuzumab Ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
119. Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells
120. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: Results of the United Kingdom Medical Research Council's 10th AML trial
121. Differential usage of three exons generates at least five different mRNAs encoding human leukocyte common antigens
122. Studies on diverse inducers of differentiation on leukemic cells
123. All-trans-retinoic acid in acute promyelocytic leukemia
124. Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemias, including chronic myelogencus leukemia in blast crisis
125. Marrow transplantation for acute nonlymphoblastic leukemia in first remission
126. The leukocyte common antigen family
127. Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: A report from the Children's Cancer Group
128. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria
129. Localization of radiolabeled anti-myeloid antibodies in a human acute leukemia xenograft tumor model
130. p53 function and dysfunction
131. Lymphoma regression induced by monoclonal antiidiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein
132. Engagement of the CD19 receptor on human B-lineage leukemia cells activates LCK tyrosine kinase and facilitates radiation-induced apoptosis
133. Three-dimensional structure of recombinant human granulocyte-macrophage colony-stimulating factor
134. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
135. Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells
136. Biochemical and genetic control of apoptosis: Relevance to normal hematopoiesis and hematological malignancies
137. Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein
138. Harvey murine sarcoma virus p 21 ras protein: Biological and biochemical significance of the cysteine nearest the carboxy terminus
139. Timed- sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group
140. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell
141. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
142. Autocrine secretion of GM-CSF in acute myeloblastic leukemia
143. Calicheamicin gamma 1I and DNA: Molecular recognition process responsible for site-specificity
144. Calicheamicin gamma 1I: An antitumor antibiotic that cleaves double-stranded DNA site specifically
145. Mechanisms of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells
146. Multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16 or FAB M4Eo subtype
147. Cellular drug resistance profiles in childhood acute myeloid leukemia: Differences between FAB types and comparison with acute lymphoblastic leukemia